Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published on July 28
Following GSK's $500 million deal with Jiangsu Hengrui, global pharmaceutical giants are actively seeking Chinese innovation partners. These companies could be next in line for similar lucrative agreements.
China's biopharma sector is rapidly advancing with novel drug candidates that global companies desperately need to fill their pipelines. The potential for breakthrough discoveries is creating massive value opportunities.
Partnership deals in this sector often involve substantial upfront payments, milestone bonuses, and ongoing royalties. A single licensing agreement can transform a company's valuation overnight.
Following GSK's landmark $500 million licensing deal with Jiangsu Hengrui, we're seeing a strategic shift where global pharmaceutical giants are turning to Chinese innovators to enhance their drug pipelines. This signals growing recognition of China's biopharmaceutical sector as a critical source of novel drug innovation and creates opportunities for similar lucrative partnerships.
These Chinese biopharma companies focus on developing promising drug candidates through early-stage trials before seeking larger partners for late-stage development and global commercialization. The investment appeal lies in potential value uplift from upfront payments, milestone achievements, and future royalties from partnership agreements.
This group was carefully curated to include innovative Chinese biopharma companies with advanced research and development capabilities that are creating valuable intellectual property. These firms are well-positioned to secure their own lucrative licensing and partnership agreements as global pharma companies increasingly seek external innovation.
Interpretation for the basket 'China's Biopharma Innovators: The Next Global Partnership Wave' market cap data.
HCM: $2.67B
ZLAB: $3.28B
IMAB: $591.31M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+5
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+382.17%
On average, analysts expect assets in this group to grow 382.17% over the next year.
13 of 13 assets in this group are rated Buy by professional analysts.
